COVID-19 Researchers

Medicine & Life Sciences

1. Infections 100%
2. Coronavirus 74%
3. HIV 73%
4. Alzheimer Disease 72%
5. Genes 64%
6. Therapeutics 64%
7. T-Lymphocytes 62%
8. Lung 62%
9. Viruses 61%
10. Antibodies 57%
11. West Nile virus 57%
12. SARS Virus 54%
13. Pediatrics 51%
14. Sepsis 49%
15. Mortality 49%
16. Virus Diseases 46%
17. Proteins 46%
18. Wounds and Injuries 44%
19. Severe Acute Respiratory Syndrome 43%
20. Heart Failure 43%
21. Filarial Elephantiasis 41%
22. Lung Transplantation 41%
23. Child 41%
24. Confidence Intervals 41%
25. Parkinson Disease 40%
26. Anti-Bacterial Agents 40%
27. Immunity 40%
28. Dendritic Cells 39%
29. Vaccines 39%
30. Population 39%
31. Mutation 38%
32. West Nile Fever 38%
33. Depression 37%
34. Brain 35%
35. Transplants 35%
36. Interferons 34%
37. Antiviral Agents 34%
38. Randomized Controlled Trials 34%
39. Macrophages 33%
40. Inflammation 32%
41. Antigens 32%
42. Pandemics 32%
43. Survival 31%
44. Cytokines 29%
45. Monoclonal Antibodies 29%
46. Cohort Studies 28%
47. Hospital Emergency Service 28%
48. Allografts 28%
49. Monocytes 28%
50. Biomarkers 28%
51. Odds Ratio 27%
52. Intensive Care Units 27%
53. Elderly 27%
54. Kidney 27%
55. Phenotype 27%
56. Epitopes 27%
57. Dengue Virus 27%
58. Messenger RNA 26%
59. Transplant Recipients 26%
60. Genome 26%
61. Zika Virus 26%
62. Epidemiology 26%
63. B-Lymphocytes 25%
64. Vesicular Stomatitis 25%
65. Transcription Factors 24%
66. Gene Expression 24%
67. Neoplasms 23%
68. Vaccination 23%
69. Occupational Groups 23%
70. Delivery of Health Care 23%
71. Flavivirus 23%
72. Stroke 23%
73. Cerebrospinal Fluid 23%
74. Head and Neck Neoplasms 23%
75. Amyloid 23%
76. Communicable Diseases 22%
77. Human Influenza 22%
78. RNA 22%
79. Antimicrobial Stewardship 22%
80. Asthma 22%
81. Incidence 21%
82. Systematic Reviews 21%
83. Apoptosis 21%
84. Brugia malayi 21%
85. Physicians 21%
86. Tuberculosis 21%
87. Mass Drug Administration 21%
88. Lymphocytes 21%
89. Cognitive Dysfunction 21%
90. Epithelial Cells 21%
91. Safety 21%
92. Guidelines 20%
93. Neutralizing Antibodies 20%
94. Morbidity 20%
95. Gait 20%
96. Clinical Trials 20%
97. Orthomyxoviridae 20%
98. Hemorrhage 20%
99. Comorbidity 20%
100. Neurons 20%